Cnr1 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Property |
Value |
| Gene Symbol |
CNR1 |
| Full Name |
Cannabinoid Receptor 1 |
| Chromosomal Location |
6q25.2 |
| NCBI Gene ID |
1268 |
| OMIM |
114010 |
| Ensembl ID |
ENSG00000118432 |
| UniProt ID |
P21554 |
| Associated Diseases |
Cannabis Use Disorder, Schizophrenia, Parkinson's Disease, Alzheimer's Disease |
The CNR1 gene encodes the cannabinoid receptor type 1 (CB1), a G protein-coupled receptor that is the most abundant cannabinoid receptor in the brain. It is the primary target of Δ9-tetrahydrocannabinol (THC), the psychoactive component of cannabis.
- Couples to Gi/o proteins to inhibit adenylyl cyclase
- Modulates neurotransmitter release (glutamate, GABA, dopamine)
- Involved in appetite regulation and energy metabolism
- Plays role in memory and learning (especially forgetting)
- Regulates pain perception and emotional responses
- Cannabis Use Disorder: CNR1 variants associated with cannabis dependence
- Reward processing: Altered endocannabinoid signaling in addiction
- Schizophrenia: Genetic associations with psychosis risk
- Parkinson's Disease: CB1 receptor changes in basal ganglia, potential therapeutic target
- Alzheimer's Disease: Endocannabinoid system alterations, neuroprotective potential
- Huntington's Disease: CB1 receptor loss in basal ganglia
- Multiple System Atrophy: Dysregulated endocannabinoid signaling
CNR1 is highly expressed in:
- Basal ganglia (globus pallidus, substantia nigra pars reticulata)
- Cerebellum (Purkinje cells)
- Hippocampus (CA1-CA3 regions)
- Cortex (layers II-IV)
- Hypothalamus
- CB1 antagonists: Rimonabant (withdrawn for psychiatric side effects)
- Fatty acid amide hydrolase (FAAH) inhibitors: Increase anandamide levels
- Peripherally-restricted CB1 antagonists
- Allosteric modulators
- CB1 agonists for appetite stimulation (cachexia)
- Mackie K. (2006). Cannabinoid receptors. Annu Rev Pharmacol Toxicol. PMID:16402910
- Di Marzo V. (2008). Endocannabinoid signaling. Nat Rev Neurosci. PMID:18426499
- Hurd YL. (2017). Cannabis and the developing brain. Nat Rev Neurosci. PMID:28968186
The CNR1 gene encodes the CB1 cannabinoid receptor:
- G Protein Coupling: Gi/o protein-coupled receptor
- Second Messengers: Inhibits adenylate cyclase, activates MAPK pathways
- Ion Channels: Modulates calcium and potassium channels
- Presynaptic Effects: Regulates neurotransmitter release
¶ Endocannabinoid Ligands
CB1 responds to endogenous cannabinoids:
- Anandamide (AEA)
- 2-Arachidonoylglycerol (2-AG)
- N-Arachidonoyl dopamine (NADA)
CB1 receptor activation provides neuroprotection through:
- Reduced glutamate release
- Decreased calcium influx
- Activation of protective signaling pathways
- Suppression of microglial activation
- Reduced cytokine production
- Modulation of neuroinflammatory responses
- Promotes autophagy in neurons
- Clearance of protein aggregates
- Mitochondrial quality control
- CB1 receptor agonists (dronabinol, nabilone)
- CB1 receptor antagonists (rimonabant)
- Allosteric modulators
- FAAH inhibitors (increase endocannabinoids)
- Appetite stimulation
- Pain management
- Epilepsy treatment
- Multiple sclerosis
- Neurodegenerative diseases
The study of Cnr1 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Mackie K. (2006). Cannabinoid receptors as therapeutic targets. Annu Rev Pharmacol Toxicol. 46:101-122.
- Di Marzo V. (2008). Endocannabinoid signaling in the brain. Nat Rev Neurosci. 9(11):829-842.
- Hurd YL. (2017). Cannabis and the adolescent brain. Nat Rev Neurosci. 18(11):643-659.
- Piazza PV, et al. (2020). CNR1 and cannabis addiction. Addict Biol. 25(2):e12777.
- Fernández-Ruiz J, et al. (2000). Cannabinoid receptors in neurodegeneration. Pharmacol Ther. 87(2-3):109-125.
- García-González D, et al. (2019). CB1 and Alzheimer's disease. Front Aging Neurosci. 11:35.
- Walther S, et al. (2019). Cannabis and psychosis. Curr Opin Psychiatry. 32(4):300-307.
- Chiarlone A, et al. (2014). CB1 and Parkinson's disease. Mov Disord. 29(8):997-1005.